section name header

Pronunciation

ma-ra-VI-rok

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: ccr5 co.receptor antagonists

Indications

REMS


Action

  • Blocks a specific receptor on CD-4 and T-cell surfaces, which prevents CCR5-tropic HIV-1 from entering.
Therapeutic effects:
  • Decreased invasion of CD-4 and T-cells by CCR5-tropic HIV-1 resulting in viral replication.

Pharmacokinetics

Absorption: 2–33% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A isoenzyme; 8% renal excretion as unchanged drug.

Half-Life: 14–18 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown0.5–4 hr1–2 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: myocardial ischemia/infarction, orthostatic hypotension

Derm: DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS

GI: abdominal pain, appetite disorder, HEPATOTOXICITY

MS: musculoskeletal pain

Neuro: dizziness

Resp: cough, upper respiratory tract infection

Misc: fever, risk of infection, hypersensitivity reactions (including lip swelling and facial edema), immune reconstitution syndrome

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Selzentry

Canadian Brand Names

Celsentri